Blocking the survival of the nastiest by HSP90 inhibition

Paul Workman; Paul A. Clarke; Bissan Al-Lazikani

doi:10.18632/oncotarget.6971

Blocking the survival of the nastiest by HSP90 inhibition

Paul Workman, Paul A. Clarke, Bissan Al-Lazikani

Research output: Contribution to journal › Article › peer-review

9 Scopus citations

Abstract

It is now recognised that genetic, epigenetic and phenotypic heterogeneity within individual human cancers is responsible for therapeutic resistance - knowledge that is having a profound impact on current thinking and experimentation. There has been concern that molecularly targeted therapy is doomed to failure, with resistant clones emerging in response to the Darwinian selective pressure of any drug treatment. However, two studies have shown that the evolution of drug resistance can be restrained by co-administration of a pharmacologic inhibitor of the HSP90 molecular chaperone.

Original language	English (US)
Pages (from-to)	3658-3661
Number of pages	4
Journal	Oncotarget
Volume	7
Issue number	4
DOIs	https://doi.org/10.18632/oncotarget.6971
State	Published - 2016
Externally published	Yes

Keywords

HSP90

ASJC Scopus subject areas

Oncology

Access to Document

10.18632/oncotarget.6971

Cite this

@article{984cbe78438144898c3bae6baab0d7c0,

title = "Blocking the survival of the nastiest by HSP90 inhibition",

abstract = "It is now recognised that genetic, epigenetic and phenotypic heterogeneity within individual human cancers is responsible for therapeutic resistance - knowledge that is having a profound impact on current thinking and experimentation. There has been concern that molecularly targeted therapy is doomed to failure, with resistant clones emerging in response to the Darwinian selective pressure of any drug treatment. However, two studies have shown that the evolution of drug resistance can be restrained by co-administration of a pharmacologic inhibitor of the HSP90 molecular chaperone.",

keywords = "HSP90",

author = "Paul Workman and Clarke, {Paul A.} and Bissan Al-Lazikani",

year = "2016",

doi = "10.18632/oncotarget.6971",

language = "English (US)",

volume = "7",

pages = "3658--3661",

journal = "Oncotarget",

issn = "1949-2553",

publisher = "Impact Journals",

number = "4",

}

TY - JOUR

T1 - Blocking the survival of the nastiest by HSP90 inhibition

AU - Workman, Paul

AU - Clarke, Paul A.

AU - Al-Lazikani, Bissan

PY - 2016

Y1 - 2016

N2 - It is now recognised that genetic, epigenetic and phenotypic heterogeneity within individual human cancers is responsible for therapeutic resistance - knowledge that is having a profound impact on current thinking and experimentation. There has been concern that molecularly targeted therapy is doomed to failure, with resistant clones emerging in response to the Darwinian selective pressure of any drug treatment. However, two studies have shown that the evolution of drug resistance can be restrained by co-administration of a pharmacologic inhibitor of the HSP90 molecular chaperone.

AB - It is now recognised that genetic, epigenetic and phenotypic heterogeneity within individual human cancers is responsible for therapeutic resistance - knowledge that is having a profound impact on current thinking and experimentation. There has been concern that molecularly targeted therapy is doomed to failure, with resistant clones emerging in response to the Darwinian selective pressure of any drug treatment. However, two studies have shown that the evolution of drug resistance can be restrained by co-administration of a pharmacologic inhibitor of the HSP90 molecular chaperone.

KW - HSP90

UR - http://www.scopus.com/inward/record.url?scp=84957998919&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84957998919&partnerID=8YFLogxK

U2 - 10.18632/oncotarget.6971

DO - 10.18632/oncotarget.6971

M3 - Article

C2 - 26820296

AN - SCOPUS:84957998919

SN - 1949-2553

VL - 7

SP - 3658

EP - 3661

JO - Oncotarget

JF - Oncotarget

IS - 4

ER -

Blocking the survival of the nastiest by HSP90 inhibition

Abstract

Keywords

ASJC Scopus subject areas

Access to Document

Other files and links

Fingerprint

Cite this